S&P Places Johnson & Johnson on CreditWatch Negative
S&P Global Ratings placed Johnson & Johnson on CreditWatch with negative implications, citing its nearly $15 billion deal to acquire mental-illness drug developer Intra-Cellular Therapies.
Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal
Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.
Johnson & Johnson’s Strategic Acquisition of Intra-Cellular Therapies: Balancing Short-term Dilution with Long-term Growth Potential
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tim ...